Showing posts with label HIV. Show all posts
Showing posts with label HIV. Show all posts

Saturday, 22 February 2014

Cancer to hit 24m Cases annually in 20 years



One the eve of World Cancer day, a report released on from the International Agency for Research on Cancer (IARC) shows some disappointing figures for the global fight against cancer. By 2030, cancers are expected to jump from 14 million in 2012 to 21.6 million a year, and overall deaths are expected to increase from 8.2 million to 13 million annually.

 Lung cancer is the biggest killer, and the report criticizes tobacco companies' push into poorer countries. It said a smoking “epidemic” is “potentially impeding human development by consuming scarce resources, increasing pressures on already weak health-care systems, and inhibiting national productivity.”

The world is facing a "tidal wave" of cancer, and restrictions on alcohol and sugar need to be considered, say World Health Organization scientists.
It predicts the number of cancer cases will reach 24 million a year by 2035, but half could be prevented.

In Uganda, some 3000 new people afflicted with various cancers will have presented themselves at the Uganda Cancer institute (UCI), the only cancer referral facility in the country for treatment by the end of 2014. 

This is because of the increase in infections malaria, HIV, Hepatitis B, Human Papilloma Virus (HPV) and typhoid. Infection-related cancers include Burkitt’s lymphoma, associated with malaria and affects children between four and seven years, Kaposi's sarcoma caused by the Human Herpes Virus 8 (HHV8) whose risk increases dramatically in people with HIV infection and Hepatocellular Carcinoma (cancer of the liver) caused by the Hepatitis B Virus (HBV).
The UCI director, Dr. Jackson Orem says HIV has accelerated the burden of cancer in the country so much so that 60 percent of cancers in adults at UCI are related to HIV.
“Thirty percent of cancers in developing countries are related to infection. Most cancer patients in Uganda are young and in their prime as opposed to elderly population in the developed world,” he said in an interview with the Observer.
Dr. Orem adds that institute is seeing an influx of children afflicted with Burkett’s lymphoma, a potentially fatal and disfiguring cancer that often develops in the jaw or abdomen caused by the Epstein-Barr virus that is as a result of frequent and ill-treated malaria.

Other infection related cancers include; blood, cervical, bladder and stomach cancers.
Worldwide, cancer kills more people than AIDS, tuberculosis, and malaria combined and has become a leading cause of death in the world. (WHO) estimates that by 2030 more than 12 million people could die from cancer related diseases. About 80 per cent of these deaths are likely to occur in low-income and middle-income countries such as Uganda.
Currently, according to information from the Non-communicable disease unit of the health ministry, 300 people per every 100,000 are estimated to have cancers
Last year, UCI recorded a total of 2800 patients with infection related cancers last year accounting for more than 50 per cent of the cancer burden in the country.
“If the infections are not reduced sooner than later, cancer is going to be the next big epidemic in the country,” Dr Fred Okuku, a senior oncologist at UCI warns.
The WHO said there was now a "real need" to focus on cancer prevention by tackling smoking, obesity and drinking.
The World Cancer Research Fund said there was an "alarming" level of naivety about diet's role in cancer.

Fourteen million people a year are diagnosed with cancer, but that is predicted to increase to 19 million by 2025, 22 million by 2030 and 24 million by 2035.
The developing world will bear the brunt of the extra cases.
Dr Chris Wild, the director of the WHO's International Agency for Research on Cancer, told the BBC: "The global cancer burden is increasing and quite markedly, due predominately to the ageing of the populations and population growth.

“If we look at the cost of treatment of cancers, it is spiralling out of control, even for the high-income countries. Prevention is absolutely critical and it's been somewhat neglected.”
The WHO's World Cancer Report 2014 said the major sources of preventable cancer included:
·         Smoking
·         Infections
·         Alcohol
·         Obesity and inactivity
·         Radiation, both from the sun and medical scans
·         Air pollution and other environmental factors
·         Delayed parenthood, having fewer children and not breastfeeding
For most countries, breast cancer is the most common cancer in women. However, cervical cancer dominates in large parts of Africa.
The human papillomavirus (HPV) is a major cause. It is thought wider use of the HPV and other vaccines could prevent hundreds of thousands of cancers.

One of the report's editors, Dr Bernard Stewart from the University of New South Wales in Australia, said prevention had a "crucial role in combating the tidal wave of cancer which we see coming across the world".
Dr Stewart said human behavior was behind many cancers such as the sunbathe "until you're cooked evenly on both sides" approach in his native Australia.

He said it was not the role of the International Agency for Research on Cancer to dictate what should be done.

But he added: "In relation to alcohol, for example, we're all aware of the acute effects, whether it's car accidents or assaults, but there's a burden of disease that's not talked about because it's simply not recognised, specifically involving cancer.

“The extent to which we modify the availability of alcohol, the labelling of alcohol, the promotion of alcohol and the price of alcohol - those things should be on the agenda.”

He said there was a similar argument to be had with sugar fuelling obesity, which in turn affected cancer risk.

Meanwhile, UCI has been chosen by the International Atomic Energy Agency (IAEA) to host the Virtual University for Cancer Control (VUCCnet)- a regional centre for excellence for Cancer training in East Africa.
Currently, the modern Lymphoma Treatment Centre is nearing completion and it is expected to accommodate 100 patients at any one time.

Friday, 27 September 2013

EXPERTS TO REPORT ON ADVANCES IN THE SEARCH FOR THE ULTIMATE HIV PREVENTION TOOL - A VACCINE - AT AIDS VACCINE 2013


Progress, Partnership and Perseverance is the Theme of the Leading Global Conference on HIV Vaccine Research


(NEW YORK, NEW YORK and BARCELONA, SPAIN) - More than 450 research studies outlining the latest advances and obstacles in the search for an AIDS vaccine will be presented and debated at AIDS Vaccine 2013, the world's only scientific meeting dedicated exclusively to HIV vaccine research. The conference, which runs Monday, 7 October through Thursday, 10 October, will bring more than 1,000 of the world's leading vaccine researchers, funders and policy makers to the International Convention Center in Barcelona, Spain for four days of exchange, debate and direction-setting for the field.


AIDS Vaccine 2013 is organized by the Global HIV Vaccine Enterprise and by this year's local conference hosts, the HIVACAT Program for HIV Vaccine Research,based in Barcelona.

A vaccine that could help to stop the global HIV/AIDS epidemic is one of the most-sought-after goals of modern scientific research, and among the most complex scientific challenges ever undertaken.  Researchers meeting at AIDS Vaccine 2013 will report on several recent advances in the field, including:
  • Progress in the study of several candidate vaccines being tested globally;
  • Updates on strategies to better understand and increase the modest protection observed in the RV144 trial, the first study to reduce HIV infection risk through vaccination; This HIV vaccine clinical trial started in Thailand in 2003 and the first results were presented in 2009, showing modest protection from HIV infection;
  • Advances in efforts to engineer immunogens capable of inducing the neutralizing antibodies that could form the basis of future vaccine candidates; and
  • Novel vaccination strategies being investigated in non-human primates.
AIDS Vaccine 2013 opens as the field is also working to learn the lessons from studies such as HVTN 505, a phase 2b clinical trial stopped earlier this year when the vaccine tested was found to be ineffective.  Researchers are studying the lessons of this and other trials to determine how to better predict complex immune responses that can help ensure protection against HIV infection.

"Progress, partnership and perseverance are the themes of this conference, and all three will be on display at AIDS Vaccine 2013," said Bill Snow, director of the Global HIV Vaccine Enterprise.  "As we meet in Barcelona, huge strides are being made in efforts to understand and replicate the development of broadly neutralizing antibodies, which could be the basis for powerful new vaccine candidates.  We are also seeing a flowering of cross-disciplinary and cross-institutional collaborations in vaccine research, as well as surprising new findings from individual labs and sophisticated animal studies."

“Transforming advances in the lab into vaccine candidates for clinical trials will be high on the list of priorities for researchers, funders and policy makers meeting in Barcelona,” noted conference co-chair, Bonaventura Clotet, M.D. of the Institute for AIDS Research IrsiCaixa and codirector of the HIVACAT Program for HIV Vaccine Research.  

“Our ultimate challenge is to develop a vaccine that is not only safe and effective against HIV, but also practical in real world settings.”
"AIDS Vaccine 2013 will feature more than 450 research presentations selected from a record number of abstracts," said conference co-chair, Josep M. Gatell, M.D., Ph.D., of the Hospital ClĂ­nic-IDIBAPS, University of Barcelona and codirector of the HIVACAT Program for HIV Vaccine Research.  

"The vibrancy of the field is demonstrated not only by the volume of outstanding research to be presented, but also by the fact that more than 50 percent of conference presentations will highlight the research of the young and early-career investigators, whose energy and new ideas represent the future of HIV vaccine science."
Among the additions to this year's conference program are a symposium session on therapeutic vaccines, and an additional plenary session with updates on the latest HIV vaccine clinical trial results, including HVTN 505. 
  
The conference opening session, on Monday 7 October, will elaborate on the Progress, Partnership and Perseverance theme with presentations from Anthony Fauci of the U.S. National Institutes of Health, the world's largest funder of AIDS vaccine research; vaccine development pioneer Stanley Plotkin; AIDS vaccine study, HVTN 505, Principal Investigator Magda Sobiesczcyk; Ntando Yola of the Networking HIV/AIDS Community of South Africa (NACOSA), a South African civil society network; Bill Snow of the Global HIV Vaccine Enterprise, a collaborative of the world's leading HIV vaccine researchers and funders; HIVACAT codirectors Josep M. Gatell and Bonaventura Clotet; Catalonia Minister of Health, Boi Ruiz i Garcia; and Enric Banda, director of Science, Research and the Environment of the vaccine research funder "la Caixa" Foundation.

"AIDS Vaccine 2013 presents a critical opportunity to highlight Spain's commitment to HIV vaccine research," said Christian Brander, Ph.D., scientific director of the HIVACAT Program and ICREA Research Professor at IrsiCaixa. 

 "Advances in HIV prevention, including the use of antiretroviral drugs to reduce transmission and infection, expanded access to voluntary medical male circumcision and promising research on microbicides to prevent infection in women and men are all contributing to important decreases in new infections.  At the same time, a safe and effective vaccine remains the key missing piece in efforts to drive down new HIV infections
worldwide and control the pandemic."

The growing interconnection among various biomedical approaches to HIV prevention has brought leaders in different research fields together to establish a new, unified HIV prevention research conference beginning in 2014.  Building on the tradition of the annual HIV vaccine and microbicide research meetings, the new biennial conference, HIV Research for Prevention: Vaccine, Microbicide and ARV-based Prevention Science (HIV R4P) (Cape Town, South Africa, 28-31 October 2014), will bring together the full spectrum of biomedical HIV prevention research.
"HIV R4P will promote the cross-fertilization of research and synergies in HIV prevention strategies that can lead to significant, ongoing reductions in the global epidemic," said Robin Shattock, professor of Mucosal Infection and Immunity, Imperial College, London. 

"The new HIV R4P conference will help ensure that all of the potential synergies in research and implementation between different prevention approaches, including vaccine research, are fully explored in a format that will draw global attention to the promise of both new and established approaches to HIV prevention."



Facebook and Twitter
Conference participants will keep up with what is happening at AIDS Vaccine 2013 and share their updates with the broader community through Facebook @HIVEnterprise and Twitter, #AIDSVax2013, as well as through the Twitter accounts of two of HIVACAT's leading institutions: @IrsiCaixa and @IDIBAPS_EN